SALT LAKE CITY, Feb. 25, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that results from a recent study at community oncology practices indicate that 41% of patients receiving care were appropriate assessment candidates for genetic testing for hereditary breast and ovarian cancer syndrome based on BRCA mutations. The article, entitled: “Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices,” was published in the February 2010 issue of the journal Community Oncology. This study is one of the first to assess the percentage of patients who meet professional society guidelines and would benefit from genetic risk assessment in the community oncology practice setting and underscores the importance of physicians integrating genetic testing processes into their practices.
